secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001645113-25-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure FY2024 revenue $605M (+19%), Q4 net loss $65.9M; Optune Lua approved and launched; PANOVA-3 trial met endpoint
--------------------------------------------------------------------------------

- FY2024 net revenues $605.2M (+19% YoY); Q4 net revenues $161.3M (+21% YoY).
- Q4 net loss $65.9M ($0.61/sh); adjusted EBITDA $2.6M; cash $959.9M.
- Optune Lua received FDA approval Oct 2024 for metastatic NSCLC; 52 prescriptions by year-end.
- Phase 3 PANOVA-3 trial met primary endpoint in unresectable locally advanced pancreatic cancer.
- 2025 outlook: low mid-single digit GBM growth; margins impacted by product launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000003/0001645113-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000003/nvcr-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer